Who is sponsoring NCT01927406?

NCT01927406 is sponsored by Stanford University.

What condition does NCT01927406 study?

NCT01927406 studies Thyroid Eye Disease, Ocular Hypertension, Glaucoma.

What drugs are being tested in NCT01927406?

Interventions: Prostaglandin Analog, Timolol.

What is the status of NCT01927406?

NCT01927406 is currently WITHDRAWN.

Last reviewed 2018-05-14 · How we verify

The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients.

NCT01927406 Phase 4 WITHDRAWN

The purpose of this study is to evaluate the potential secondary beneficial effect of prostaglandin analogues (PA) treatment in thyroid eye disease (TED) patients. This study aims to determine if PA would change the course of the orbitopathy in TED patients by altering the progression of the common features of TED, including fatty hypertrophy, proptosis, eyelid retraction and optic nerve compression. The eyes with thyroid eye disease and elevated intraocular pressure will be randomised to the PA treatment and the other eye will serve as a control eye and will be treated with Timolol.

Details

Lead sponsor	Stanford University
Phase	Phase 4
Status	WITHDRAWN
Start date	2014-06
Completion	2016-12

Conditions

Thyroid Eye Disease
Ocular Hypertension
Glaucoma

Interventions

Prostaglandin Analog
Timolol

Primary outcomes

Change from baseline in appearance of facial periorbital region at 6 months. — Baseline and 6 months

Countries

United States